热门资讯> 正文
Emergent BioSolutions为口服悬浮液TEMBEXA获得价值1700万美元的合同修改
2025-09-15 20:54
- Emergent BioSolutions (NYSE:EBS) announced on Monday it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to supply TEMBEXA oral suspension.
- The contract modification follows the U.S. Food and Drug Administration’s recent approval of the manufacturing scale-up of TEMBEXA oral suspension.
- The company said the newly exercised contract modification to supply TEMBEXA builds upon the previously announced options from September 2024, and are all under Emergent’s existing 10-year contract.
- EBS +1.96% premarket to $8.3.
- Source: Press Release
More on Emergent Biosolutions
- Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
- Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
- Mpox in Africa is no longer a global health emergency, WHO chief says
- Emergent Biosolutions awarded $30 million contract modification for CYFENDUS
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
